Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors

BACKGROUND: Older adults aged 65 years and above remain underrepresented in cancer clinical trials. We hypothesized that older participation in early phase trials with VEGF/VEGFR (VEGF/R) inhibitors was lower than cancer prevalence in this group and lower than other age groups (middle age, adolescen...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Ishwaria M., Tang, Chad, Rao, Arvind, Falchook, Gerald S., Subbiah, Vivek, Tsimberidou, Apostolia M., Karp, Daniel, Kurzrock, Razelle, Hong, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034739/
https://www.ncbi.nlm.nih.gov/pubmed/29989021
http://dx.doi.org/10.18632/oncotarget.25571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034739/
https://www.ncbi.nlm.nih.gov/pubmed/29989021
http://dx.doi.org/10.18632/oncotarget.25571

Ejemplares similares